about
ABO-Mismatched Allogeneic Hematopoietic Stem Cell TransplantationWhy has demand for platelet components increased? A reviewAutologous Hematopoietic Stem Cell Transplantation-10 Years of Data From a Developing CountryIncreased age-associated mortality risk in HLA-mismatched hematopoietic stem cell transplantation.Hematopoietic SCT in Europe: data and trends in 2012 with special consideration of pediatric transplantationPediatric hematopoietic stem cell transplantation in China: Data and trends during 1998-2012.Economic and clinical aspects of intravenous versus oral busulfan in adult patients for conditioning prior to HSCT.European Group for Blood and Marrow Transplantation Centers with FACT-JACIE Accreditation Have Significantly Better Compliance with Related Donor Care Standards.Allogeneic hematopoietic stem cell transplantation in patients with advanced indolent lymphoproliferative disorders.Outcomes of autologous or allogeneic stem cell transplantation for non-Hodgkin lymphoma.Adoptable strategic approaches to improve outcomes of allogeneic peripheral blood stem cell transplantations from unrelated donors.Long-active granulocyte colony-stimulating factor for peripheral blood hematopoietic progenitor cell mobilization.Plerixafor for mobilization of blood stem cells in autologous transplantation: an update.Current status of haematopoietic autologous stem cell transplantation in lymphoid malignancies: a European perspective.The role of hematopoietic stem cell transplantation in chronic myeloid leukemia.The immune response to cytomegalovirus in allogeneic hematopoietic stem cell transplant recipients.Erythrocyte depletion from bone marrow: performance evaluation after 50 clinical-scale depletions with Spectra Optia BMC.Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel.Family members' life situation and experiences of different caring organisations during allogeneic haematopoietic stem cells transplantation-A qualitative study.Voriconazole for prophylaxis of invasive fungal infections after allogeneic hematopoietic stem cell transplantation.Cancer-and-treatment-specific distress and its impact on posttraumatic stress in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT).Hematopoietic Stem Cell Transplantation: A Bioethical Lens.Differences in epidemiology of candidaemia in the Nordic countries - what is to blame?Engraftment and outcomes following autologous stem cell transplantation in Hodgkin lymphoma patients mobilized with plerixafor.Sexual function 1-year after allogeneic hematopoietic stem cell transplantation.Risk factors and prophylaxis against invasive fungal disease for haematology and stem cell transplant recipients: an evolving field.Clinical features of life-threatening complications following autologous stem cell transplantation in patients with lymphoma.Feasibility of an exercise programme in elderly patients undergoing allogeneic stem cell transplantation - a pilot study.Unmanipulated haploidentical bone marrow transplantation and post-transplant cyclophosphamide for hematologic malignanices following a myeloablative conditioning: an update.Changes in intensive care for allogeneic hematopoietic stem cell transplant recipients.Circulating endothelial cell enumeration demonstrates prolonged endothelial damage in recipients of myeloablative allogeneic stem cell transplantation.Plerixafor in patients with lymphoma and multiple myeloma: effectiveness in cases with very low circulating CD34+ cell levels and preemptive intervention vs remobilization.High prevalence of distress in patients after allogeneic hematopoietic SCT: fear of progression is associated with a younger age.Determinants of exercise adherence and contamination in a randomized controlled trial in cancer patients during and after allogeneic HCT.Short-term side effects and attitudes towards second donation: A comparison of related and unrelated haematopoietic stem cell donors.Myeloablative conditioning regimens with combined of haploidentical and cord blood transplantation for myelodysplastic syndrome patients.Conflicting HLA assignment by three different typing methods due to the apparent loss of heterozygosity in the MHC region.Red blood cell depletion from bone marrow and peripheral blood buffy coat: a comparison of two new and three established technologies.Deferrals of volunteer stem cell donors referred for evaluation for matched-unrelated stem cell donation.Impact of recipient ABH secretor status on outcome in minor ABO-incompatible hematopoietic stem cell transplantation.
P2860
Q26750395-9DFB1599-2659-4FB6-A725-465A75452C90Q28249969-87B386F6-5FF0-4554-A447-477DF0CF65ABQ30962747-6C9D859F-ADC8-4DCF-9D43-6368BC961555Q33574209-87491C3D-1110-4574-8208-6F95CF610A09Q33733022-1F57E5CB-1958-4853-B265-FCFC23EF50A9Q35658742-DA30993B-AF3A-4D1B-A5DE-86AEA769844FQ36220882-036524C3-095D-43C2-973F-E713B9BD97FCQ36597561-68B8DBF7-5972-4EC1-AAE1-D772B48206ACQ36928725-9FD24E6D-1D54-4EF7-9896-5B8224EC5380Q37212916-27923DB1-65CD-4CEB-A857-506744AE191CQ38164819-5D9DE73A-73C2-4875-9EBD-D541B4C3DB94Q38193590-4B300FD2-9E91-4FCA-A889-C6AFD8CF826EQ38199707-AC0D3783-462F-448B-837C-D7C02AB879F1Q38209433-E772F64B-F8FF-4A5B-8AE1-7EAF808686DDQ38392690-AB862F56-FE7A-45C0-833C-FDC9E7D36A95Q38547042-0C144EA8-50FF-4726-BB94-7732EE935AF4Q38628563-2ECD8566-114B-48BF-B660-7762F3DD9FFAQ39092515-7A6A7600-5B13-431D-B87C-88695BAF1CF0Q39176991-838B16B1-976B-4932-B217-1187967F40B5Q39196770-565D7E36-3EDC-4E6C-B0E6-72481B34E178Q39309946-049FAA21-B536-44E2-ABE9-50D51E4ED6D0Q39455760-01CDC3A3-427C-4DEF-934E-D19E8B137FC4Q39553745-427316DE-A50E-4E2E-A6C4-C1136C54C5B4Q39958361-8A0AE8BD-5FB0-4868-AA9B-B07D4E96E1F5Q39996008-4CFF99E2-1BB5-44EC-99AE-A070DC06DAD3Q40515140-398E207B-9EF2-4D67-8435-8CDF16BA4F73Q41153838-AFA98D47-EE91-4A99-85A7-1D96C8A12711Q41157348-DAD7B647-FE38-4593-AEDA-3910B79CCDAEQ41188019-4D2B9717-770A-4EF0-A8C8-2BFE82BB908AQ41394915-ABDB1C6C-1AAC-404D-AC03-510C0BBDC143Q42847647-2B9F18CE-D302-45F4-9FE5-843BCACBD198Q44256421-0DB85EBE-5540-4E71-9E9B-81FC484352AAQ47928634-1F8B95FB-814A-4EA6-8CAA-52BDDDFD5008Q48022179-3A76F13A-22C1-4453-B52D-B8117B510615Q48192483-402DAD3A-84AD-4CFD-81A3-D0C1E292CC68Q48616629-798D936D-F9BA-4D90-97A8-CD95D803CE23Q50249146-927C43D9-8D78-4340-BDF6-41A1BF55660DQ50452458-C71CA2AC-6BD3-4B87-9EDC-A115E01E176CQ50463607-524FEDDA-AC0B-41C4-8C6B-214BF2AF5CEDQ50466984-4EA82059-09C1-4AB2-8235-DE1CEAC30260
P2860
description
2013 nî lūn-bûn
@nan
2013 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Hematopoietic SCT in Europe: data and trends in 2011.
@ast
Hematopoietic SCT in Europe: data and trends in 2011.
@en
type
label
Hematopoietic SCT in Europe: data and trends in 2011.
@ast
Hematopoietic SCT in Europe: data and trends in 2011.
@en
prefLabel
Hematopoietic SCT in Europe: data and trends in 2011.
@ast
Hematopoietic SCT in Europe: data and trends in 2011.
@en
P2093
P2860
P50
P356
P1476
Hematopoietic SCT in Europe: data and trends in 2011
@en
P2093
C Ruiz de Elvira
D Farge-Bancel
European Group for Blood and Marrow Transplantation
H Baldomero
H Bobby Gaspar
J H F Falkenburg
P2860
P2888
P304
P356
10.1038/BMT.2013.51
P407
P577
2013-04-15T00:00:00Z
P5875
P6179
1048575699